The Food and Drug Administration issued a revised final guidance on Friday that provides updated recommendations on the use of COVID-19 convalescent plasma (CCP) related to the December 2021 emergency use authorization (EUA) for CCP.
The Food and Drug Administration revised the emergency use authorization (EUA) for COVID-19 convalescent plasma (CCP) on Dec. 28 to permit the use of high-titer CCP for treatment of COVID-19 in patients with immunosuppressive disease or receiving immunosuppressive treatment.
The slide presentation from the 2021 AABB Virtual Annual Meeting session “Ask the FDA and CLIA/CMS” is now available with responses from each agency’s representatives included in the slides.
AABB announces the availability of a new toolkit on HIV testing, lookback and re-entry. Developed at member request, it is the first in a series of resources created to assist blood centers and transfusion services with the regulatory actions necessary following a positive test for an RTTI.
As part of its #PBMAW2021 activities, AABB is pleased to offer the blood community complimentary access to an eCast on patient blood management (PBM) certification.
